Description
Molndal, Sweden – 30 October 2013 – Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be presenting new data at Neuroscience 2013, 9-13 November, San Diego (USA). In a series of poster presentations, Cellectricon (booth #933) will demonstrate how its technology can be applied effectively for drug discovery, particularly in relation to cytoskeletal disorders and neurodegenerative diseases.Cellectricon’s novel approach is based around electric field stimulation, and the posters, which include primary data, detail how the Cellaxess technology can be used to deliver pharmacologically active molecules to neuronal cultures without compromising cell viability or functionality. The poster session will also reveal an assay for the high-throughput identification of compounds that modulate neuronal excitability. In this way, attendees will be shown how compound characterization and data-based decision making can be achieved early in a project life-cycle, reducing unnecessary time and cost.
The poster presentations take place on 11-13 November, and Cellectricon employees will be on-hand to answer any questions you may have during this time. Please visit the Cellectricon website for more information on the content of the posters, or follow the links below. Cellectricon will also be exhibiting at booth #933, so drop by to learn more about Cellectricon’s Discovery Services, launched earlier this year.
